JBIO — Jade Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1798749 ·
Last close
$20.95
Market Cap
$1.28B
52W High
$28.00
52W Low
$14.28
ADV30
1,457,578
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -43,445,000 | -40,368,000 | 319,433,000 | 55,085,000 | 22,971,000 |
| Dec 2025 | 0 | — | -34,979,000 | -31,932,000 | 349,781,000 | 88,438,000 | 17,263,000 |
| Sep 2025 | 0 | — | -27,401,000 | -25,175,000 | 202,450,000 | 50,106,000 | 23,104,000 |
| Jun 2025 | 0 | — | -27,778,000 | -32,134,000 | 223,968,000 | 220,942,000 | 22,412,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,387,000
Investing CF
$-246,870,000
Financing CF
$262,160,000
CapEx
$-60,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.03
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,389,000
Inventory
—
Receivables
$0
ST Investments
$247,720,000
EBIT TTM
$-110,141,000
Pretax Income TTM
$-119,295,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,542,000 | -127,410,000 | 349,781,000 | 17,263,000 | — | -94,689,000 |
| Dec 2024 | — | — | — | 72,799,000 | 119,598,000 | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-27,430,000
OpCashFlow TTM
$0
Assets (Latest)
$127,418,000
Forward EPS
$-2.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | $1.26B | $36.24 | — |
| MNKD | MANNKIND CORP | $1.26B | $4.09 | — |
| ARDX | ARDELYX, INC. | $1.30B | $5.28 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $1.25B | $21.51 | — |
| AVLN | Avalyn Pharma Inc. | $1.24B | $28.06 | — |
News headlines (Yahoo Finance, 1h cache)
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
2026-06-30 13:21 · Yahoo
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
2026-06-26 11:00 · Yahoo
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-06-05 20:01 · Yahoo
Jade Biosciences Announces Pricing of Public Offering of Common Stock
2026-06-04 02:58 · Yahoo
Jade Biosciences Announces Proposed Underwritten Public Offering
2026-06-03 20:01 · Yahoo
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
2026-06-02 01:07 · Yahoo
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
2026-06-01 11:00 · Yahoo
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Mo
2026-05-29 20:05 · Yahoo
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
2026-05-26 20:05 · Yahoo
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
2026-05-26 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.